Muhammad Imran has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Guanyu Wang

    Laboratory of Biocomplexity and Engineering Biology, Department of Biomedical Engineering, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; CUHKSZ-STEM Joint Laboratory of Precision Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; Ciechanover Institute of Precision and Regenerative Medicine, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China

    4 shared publications
  • Javed Akhtar

    Provincial Hospital Affiliated to Shandong University

    4 shared publications
  • Gang Ma

    Department of Biology, School of Life Sciences, Southern University of Science and Technology

    2 shared publications
  • Jiahe Wang

    Laboratory of Biocomplexity and Engineering Biology, School of Medicine, The Chinese University of Hong Kong

    2 shared publications
  • Imran Sajid

    Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering,Chinese University of Hong Kong, Shenzhen,Shenzhen,China, China

    1 shared publication
  • Jiahe Wang

    School of Biological Sciences and Parker H. Petit Institute for Bioengineering and Bioscience,Georgia Institute of Technology,Atlanta,United States, USA

    1 shared publication

Latest Publications

  • Open Access

    Single-Cell FRET Imaging: A Robust Biophysical Platform to Resolve Heterogeneity in Metabolic Dysfunction and Cancer Drug Resistance

    by Javed Akhtar, Muhammad Imran, Jiahe Wang, Imran Sajid, Guanyu Wang

    Cells with similar endpoint measurements can have different biochemical response histories. Time-lapse single-cell Förster resonance energy transfer (FRET) imaging can distinguish these histories and test their relationship to metabolic function and cancer-cell fate. We connect FRET biophysics, biosensor design, and quantitative measurement to interpret cellular heterogeneity in metabolic dysfunction and cancer drug resistance. We emphasize corrected sensitized emission FRET imaging, distinguish corrected ratios from physical transfer efficiency, and describe controls for reporter specificity, temporal fidelity, and reproducibility. In metabolism, FRET imaging can reveal graded or bistable behavior and characterize sensitivity, response amplitude, history dependence, and coupling between signaling and substrate handling. In cancer, time-lapse signaling measurements paired with independent cell-fate outcomes can distinguish incomplete inhibition, adaptive recovery, and survival despite sustained pathway suppression. Cell culture, organoid, and intravital studies illustrate these capabilities and limits. Linking calibrated response histories to independent functional outcomes provides a robust foundation for candidate dynamic biomarkers. Integrating trajectory features with molecular profiles using machine learning could identify candidate predictors of treatment response. Future studies should test whether these dynamic features improve compound selection, combination design, and treatment schedules beyond baseline activity, initial inhibition, and endpoint measurements, with validation in independent patient-derived and in vivo models.

  • Live-Cell Förster Resonance Energy Transfer Imaging of Metabolically Regulated Akt Activation Dynamics in HepG2 Cells

    by Javed Akhtar, Muhammad Imran, Jiahe Wang, Gang Ma, Guanyu Wang

    Metabolically regulated Akt activation is a critical node in the insulin signaling cascade and provides valuable insights into the relationship between diabetes and cancer. To precisely quantify Akt activity in HepG2 cells, we developed a robust, reproducible protocol utilizing Förster Resonance Energy Transfer (FRET) with genetically encoded Akt-specific biosensors. This protocol outlines detailed steps for cell culture, imaging dish preparation, and transfection of HepG2 cells to express FRET-based biosensors, alongside specific guidelines for laser scanning confocal microscope hardware and software configuration. The results demonstrated unique patterns of insulin signaling in HepG2 cells, which exhibit an irreversible switch characterized by constitutive Akt activation with a defined switch-on threshold but no switch-off threshold. In contrast, myotubes display a reversible switch. The persistent Akt activation in HepG2 cells suggests mechanisms underlying insulin resistance and metabolic dysregulation in hepatic cells, with broader implications for understanding the progression of metabolic disorders and cancer. This protocol offers a valuable framework for exploring Akt-related signaling pathways and cellular behaviors across various disease contexts.


  • JoVE Video Dataset

    by Javed Akhtar, Muhammad Imran, Jiahe Wang, Gang Ma, Guanyu Wang

    Metabolically regulated Akt activation is a critical node in the insulin signaling cascade and provides valuable insights into the relationship between diabetes and cancer. To precisely quantify Akt activity in HepG2 cells, we developed a robust, reproducible protocol utilizing Förster Resonance Energy Transfer (FRET) with genetically encoded Akt-specific biosensors. This protocol outlines detailed steps for cell culture, imaging dish preparation, and transfection of HepG2 cells to express FRET-based biosensors, alongside specific guidelines for laser scanning confocal microscope hardware and software configuration. The results demonstrated unique patterns of insulin signaling in HepG2 cells, which exhibit an irreversible switch characterized by constitutive Akt activation with a defined switch-on threshold but no switch-off threshold. In contrast, myotubes display a reversible switch. The persistent Akt activation in HepG2 cells suggests mechanisms underlying insulin resistance and metabolic dysregulation in hepatic cells, with broader implications for understanding the progression of metabolic disorders and cancer. This protocol offers a valuable framework for exploring Akt-related signaling pathways and cellular behaviors across various disease contexts.

  • Open Access

    CRISPR/Cas9-Mediated CtBP1 Gene Editing Enhances Chemosensitivity and Inhibits Metastatic Potential in Esophageal Squamous Cell Carcinoma Cells

    by Javed Akhtar, Muhammad Imran, Guanyu Wang

    Innovative therapeutic strategies for esophageal squamous cell carcinoma (ESCC) are urgently required due to the limited effectiveness of standard chemotherapies. C-Terminal Binding Protein 1 (CtBP1) has been implicated in various cancers, including ESCC. However, the precise expression patterns and functional roles of CtBP1 in ESCC remain inadequately characterized. In this study, we aimed to investigate CtBP1 expression and its role in the resistance of ESCC to paclitaxel, an effective chemotherapeutic agent. Western blotting and immunofluorescence were applied to assess CtBP1 expression in the TE-1 and KYSE-50 cell lines. We observed the marked expression of CtBP1, which was associated with enhanced proliferation, invasion, and metastasis in these cell lines. Further, we successfully generated paclitaxel resistant ESCC cell lines and conducted cell viability assays. We employed the CRISPR/Cas9 genome editing system to disable the CtBP1 gene in ESCC cell lines. Through the analysis of the drug dose–response curve, we assessed the sensitivity of these cell lines in different treatment groups. Remarkably, CtBP1-disabled cell lines displayed not only improved sensitivity but also a remarkable inhibition of proliferation, invasion, and metastasis. This demonstrates that CtBP1 may promote ESCC cell malignancy and confer paclitaxel resistance. In summary, our study opens a promising avenue for targeted therapies, revealing the potential of CtBP1 inhibition to enhance the effectiveness of paclitaxel treatment for the personalized management of ESCC.